Back to All Peptides
Fat Lossinjectable

Retatrutide

Triple-action metabolic agonist targeting GLP-1, GIP, and glucagon receptors.

Human clinical evidenceStudied in one or more human clinical trials, but not FDA-approved for this use. Evidence quality and trial size vary — see sources.

For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.

About Retatrutide

Retatrutide is an investigational triple hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. Early clinical trials have shown unprecedented weight reduction results, with the glucagon component adding direct hepatic fat oxidation and energy expenditure to the incretin-mediated appetite suppression.

Key Benefits

  • Triple receptor activation for maximum metabolic effect
  • Enhanced fat oxidation via glucagon signaling
  • Potent appetite suppression
  • Investigational — promising Phase 2 trial results

Set a goal (top of the page) to see how Retatrutide scores against it, and what the better-evidenced alternatives are.

Category Ratings

Muscle & Strength
N/A
Fat Loss
Excellent
Recovery
N/A
Skin & Anti-Aging
N/A
Sleep
N/A
Cognitive
N/A
Immune
N/A
Longevity
Minimal
Bone & Hormonal
N/A

How to Take

Injection

Subcutaneous injection into abdomen or thigh — rotate sites weekly

Common Side Effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • Constipation
  • Increased heart rate

Legal & Regulatory Status

Investigational. Phase 3 clinical trials in progress. Not yet FDA-approved.

Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.

Research & Sources

Human clinical evidenceStudied in one or more human clinical trials, but not FDA-approved for this use. Evidence quality and trial size vary — see sources.

Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.

Retatrutide

Prices at quality-checked sources · as of August 2026 (3 weeks ago)

Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.

CategoryWeight Management
Formsinjectable

Builds a working set shared across the stack builder, calculator, scheduler and compare.